Follicum AB (publ ) today reports revised top line data from a Phase IIa study of the tissue repairing peptide FOL-005 for the treatment of hair loss (alopecia). The revised data are based on an independent review that was conducted due to errors detected in the performance analysis presented by the Company on May 6, […]
Presentation BioStock Life Science Summit 2020, November 18
Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.
Read moreFollicum AB (publ ) today reports revised top line data from a Phase IIa study of the tissue repairi...
Follicum AB today announces that Jonas Edelswärd has been appointed as new CFO. He succeeds Fredrik...
Follicum AB (publ) today reports top-line data from a Phase IIa study of the tissue repairing peptid...
BioStock published an article on 3 June 2021 about Follicum, which can be read in full below. Many p...
BioStock published an article on 20 May 2021 about Follicum, which can be read in full below. Kim Ar...
BioStock published an article on 30 March 2021 about Follicum, which can be read in full below. Foll...
Follicum will attend the World Congress for Hair Research in Melbourne (WCHR), Australia, on 22-25 A...
